Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease

Eisai said that the first investigational drug candidate from its drug discovery collaboration with University College London (UCL) is set to enter Phase I clinical trials for Alzheimer's disease (AD) in early 2019.